REVB Revelation Biosciences, Inc.
-
Revelation Biosciences Missed Consensus Estimates
Thursday, August 6, 2026 · 12:00 AM ET
Revelation Biosciences (REVB) reported a loss of $0.87 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.83 per share. The company missed consensus estimates by 4.82%.
Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.87)
Earnings Whisper®
—
Consensus Estimate
($0.83)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—